Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31614288 | 1.00 | TSHR (0.54) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15846765 | 0.98 | TSHR (0.56) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL7117545 | 0.97 | TSHR (0.54) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL5828742 | 0.87 | LMNA (0.44) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15846763 | 0.83 | SNCA (0.44) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL722749 | 0.82 | SNCA (0.53) | TSHRCYP1A2CYP2C19LMNAALDH1A1 | |
| SCHEMBL8374037 | 0.80 | CYP1A2 (0.53) | TSHRCYP1A2CYP2C19LMNAALDH1A1 | |
| SCHEMBL2085893 | 0.79 | SNCA (0.53) | TSHRCYP1A2CYP2D6CYP2C19LMNA | |
| Bromide SCHEMBL6524406 | 0.79 | SNCA (0.55) | TSHRCYP1A2CYP2D6CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5427779 | 0.79 | CYP1A2 (0.51) | TSHRCYP1A2CYP2C19LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2022-10-20 | — | — | US | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| EP-3458470-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0767791-A1 | ARYL, ALKYL, ALKENYL AND ALKYNYLMACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO. INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5550233-A | AUTOIMMUNE DISEASES; PREVENTION OF TRANSPLANT REJECTION | MERCK & CO., INC. (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1995035299-A1 | ARYL, ALKYL, ALKENYL AND ALKYNYLMACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| US-5360802-A | Antagonists of cholecystokinin and gastrin | MERCK SHARPE & DOHME LTD. | 1994-11-01 | — | — | US | disclosed |
| EP-0514133-A1 | Benzodiazepine derivatives, compositions containing them and their use in therapy | MERCK SHARP & DOHME LTD. (GB) | 1992-11-19 | — | — | EP | disclosed |
| US-5093042-A | Site-specific for liver; diagnosis of metastatic cancer | THE UNIVERSITY OF MICHIGAN (US) | 1992-03-03 | — | — | US | disclosed |
| US-4957729-A | CONTRAST | THE UNIVERSITY OF MICHIGAN (US) | 1990-09-18 | — | — | US | disclosed |
| US-4873075-A | SITE-SPECIFIC TO LIVER AND HEPATOCYTE; SCINTIGRAPHY IMAGING | THE UNIVERSITY OF MICHIGAN (US) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | OPRM1 3804/4885TSHR 3832/4885CYP1A2 332/4885 |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | OPRM1 3804/4885TSHR 3832/4885CYP1A2 332/4885 |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | OPRM1 4207/4885TSHR 4178/4885CYP1A2 660/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | OPRM1 1051/4885TSHR 1823/4885CYP1A2 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.